(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of 0.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Biontech Se's revenue in 2024 is $2,924,565,217.On average, 7 Wall Street analysts forecast BNTX's revenue for 2024 to be $703,097,106,921, with the lowest BNTX revenue forecast at $631,354,949,770, and the highest BNTX revenue forecast at $784,592,910,565. On average, 7 Wall Street analysts forecast BNTX's revenue for 2025 to be $710,261,716,880, with the lowest BNTX revenue forecast at $488,795,070,588, and the highest BNTX revenue forecast at $963,174,374,349.
In 2026, BNTX is forecast to generate $708,674,389,495 in revenue, with the lowest revenue forecast at $429,244,139,370 and the highest revenue forecast at $1,106,216,918,987.